^Shigemitsu، T؛ Majima، Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical Therapeutics. ج. 18 ع. 1: 106–13. DOI:10.1016/S0149-2918(96)80183-4. PMID:8851457.
^Naoi، Makoto؛ Nomura، Yoshio؛ Ishiki، Ryoji؛ Suzuki، Hiroko؛ Nagatsu، Toshiharu (1988). "4-(O-Benzylphenoxy)-N-Methylbutylamine (Bifemelane) and Other 4-(O-Benzylphenoxy)-N-Methylalkylamines as New Inhibitors of Type A and B Monoamine Oxidase". Journal of Neurochemistry. ج. 50 ع. 1: 243–247. DOI:10.1111/j.1471-4159.1988.tb13256.x. ISSN:0022-3042.
^Kovel'man، I. R.؛ Tochilkin، A. I.؛ Gorkin، V. Z. (1991). "Structure and action of reversible monoamine oxidase inhibitors (review)". Pharmaceutical Chemistry Journal. ج. 25 ع. 8: 505–520. DOI:10.1007/BF00777412. ISSN:0091-150X.
^Dostert، P. (1994). "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?". Amine Oxidases: Function and Dysfunction. ص. 269–279. DOI:10.1007/978-3-7091-9324-2_35. ISBN:978-3-211-82521-1. For example, bifemelane [4-(O-benzylphenoxy)-N-methylbutylamine) is one of the few molecules in which both activities, reversible inhibition of MAO-A (Naoi et al., 1988) and inhibition of noradrenaline uptake (Egawa et al., 1983), although weak (IC50 = 10-6-10-7 M), coexist.
^Kondo، Y؛ Ogawa، N؛ Asanuma، M؛ Matsuura، K؛ Nishibayashi، K؛ Iwata، E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience Research. ج. 24 ع. 4: 409–14. DOI:10.1016/0168-0102(95)01017-3. PMID:8861111.
^Egashira، T؛ Takayama، F؛ Yamanaka، Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese Journal of Pharmacology. ج. 72 ع. 1: 57–65. DOI:10.1254/jjp.72.57. PMID:8902600.
